Abbott Laboratories Peer Comparison
| Metric | Value | Ranking | ||||||
|---|---|---|---|---|---|---|---|---|
| Market Cap | $196.8 Billion | 4/6 | LLY $688.9B |
JNJ $354.0B |
ABBV $303.2B |
ABT $196.8B |
BMY $114.2B |
MDT $112.9B |
| Gross Margin | 56% | 6/6 | LLY 81% |
BMY 75% |
ABBV 71% |
JNJ 70% |
MDT 65% |
ABT 56% |
| Profit Margin | 15% | 1/6 | ABT 15% |
MDT 15% |
JNJ 12% |
ABBV 11% |
BMY 10% |
LLY 8% |
| EBITDA margin | 18% | 5/6 | ABBV 49% |
BMY 38% |
JNJ 32% |
LLY 20% |
ABT 18% |
MDT 0% |
| Quarterly Revenue | $10.6 Billion | 5/6 | JNJ $22.5B |
ABBV $14.5B |
BMY $11.9B |
LLY $11.4B |
ABT $10.6B |
MDT $8.4B |
| Quarterly Earnings | $1.6 Billion | 2/6 | JNJ $2.7B |
ABT $1.6B |
ABBV $1.6B |
MDT $1.3B |
BMY $1.2B |
LLY $970.3M |
| Quarterly Free Cash Flow | $0 Billion | 4/6 | BMY $5.3B |
ABBV $5.2B |
MDT $554.0M |
ABT -$0 |
JNJ -$0 |
LLY -$458.9M |
| Trailing 4 Quarters Revenue | $41.2 Billion | 4/6 | JNJ $87.7B |
ABBV $55.5B |
BMY $47.4B |
ABT $41.2B |
LLY $40.9B |
MDT $33.0B |
| Trailing 4 Quarters Earnings | $5.8 Billion | 3/6 | JNJ $22.5B |
ABBV $14.5B |
BMY $11.9B |
LLY $11.4B |
ABT $10.6B |
MDT $8.4B |
| Quarterly Earnings Growth | 15% | 3/6 | LLY 1790% |
MDT 40% |
ABT 15% |
ABBV -12% |
BMY -37% |
JNJ -90% |
| Annual Earnings Growth | 4% | 3/6 | LLY 60% |
MDT 31% |
ABT 4% |
ABBV -35% |
JNJ -65% |
BMY -189% |
| Quarterly Revenue Growth | 5% | 3/6 | LLY 20% |
BMY 8% |
ABT 5% |
JNJ 5% |
MDT 5% |
ABBV 4% |
| Annual Revenue Growth | 3% | 4/6 | LLY 330% |
BMY 6% |
MDT 6% |
ABT 3% |
ABBV 0% |
JNJ -10% |
| Cash On Hand | $0 | 5/6 | BMY $7.9B |
ABBV $7.3B |
LLY $3.4B |
MDT $1.4B |
ABT -$0 |
JNJ -$0 |
| Short Term Debt | $0 | 5/6 | ABBV $12.6B |
MDT $3.7B |
LLY $2.1B |
BMY $1.1B |
ABT -$0 |
JNJ -$0 |
| Long Term Debt | $0 | 5/6 | ABBV $58.5B |
BMY $48.7B |
LLY $29.0B |
MDT $24.6B |
ABT $0 |
JNJ $0 |
| PE | 34.13 | 3/6 | LLY 82.31 |
ABBV 59.12 |
ABT 34.13 |
MDT 26.33 |
JNJ 24.11 |
BMY -1.00 |
| PS | 4.78 | 3/6 | LLY 16.86 |
ABBV 5.46 |
ABT 4.78 |
JNJ 4.04 |
MDT 3.42 |
BMY 2.41 |
| PB | 0.00 | 6/6 | ABBV 49.94 |
LLY 48.11 |
BMY 6.64 |
JNJ 4.95 |
MDT 2.32 |
ABT 0.00 |
| PC | -1.00 | 5/6 | LLY 204.49 |
MDT 81.02 |
ABBV 41.78 |
BMY 14.47 |
ABT -1.00 |
JNJ -1.00 |
| Liabilities to Equity | 0.00 | 5/6 | ABBV 22.77 |
BMY 4.46 |
LLY 4.30 |
MDT 0.85 |
ABT 0.00 |
JNJ -1.00 |
| ROA | -1.00 | 5/6 | LLY 11% | MDT 5% | ABBV 4% | BMY -8% | ABT -100% | JNJ -100% |
| ROE | -1.00 | 6/6 | ABBV 85% |
LLY 59% |
JNJ 21% |
MDT 9% |
BMY -42% |
ABT -100% |
| Current Ratio | -1.00 | 6/6 | MDT 2.18 |
LLY 1.23 |
BMY 1.22 |
ABBV 1.04 |
JNJ 0.00 |
ABT -1.00 |
| Quick Ratio | -1.00 | 6/6 | LLY 82.31 |
ABBV 59.12 |
ABT 34.13 |
MDT 26.33 |
JNJ 24.11 |
BMY -1.00 |
| Long Term Debt to Equity | -1.00 | 6/6 | ABBV} 9.70 |
BMY} 2.84 |
LLY} 2.04 |
MDT} 0.51 |
JNJ} 0.00 |
ABT} -1.00 |
| Debt to Equity | -1.00 | 6/6 | ABBV 11.78 |
BMY 2.90 |
LLY 2.19 |
MDT 0.58 |
JNJ 0.00 |
ABT -1.00 |
| Burn Rate | 0.00 | 5/6 | BMY 7.85 |
LLY 4.74 |
MDT 2.16 |
ABBV 1.85 |
ABT 0.00 |
JNJ 0.00 |
| Cash to Cap | 0.00 | 4/6 | BMY 0.07 |
ABBV 0.02 |
MDT 0.01 |
ABT 0.00 |
JNJ 0.00 |
LLY 0.00 |
| CCR | 0.00 | 4/6 | BMY 4.35 |
ABBV 3.33 |
MDT 0.44 |
ABT 0.00 |
JNJ 0.00 |
LLY -0.47 |
| EV to EBITDA | 101.46 | 2/6 | LLY} 318.83 |
ABT} 101.46 |
ABBV} 52.11 |
JNJ} 49.86 |
BMY} 34.08 |
MDT} -4114.00 |
| EV to Revenue | 4.78 | 3/6 | LLY 17.54 |
ABBV 6.61 |
ABT 4.78 |
MDT 4.24 |
JNJ 4.04 |
BMY 3.29 |